For several years now, scientists working on an HIV vaccine have been focused on a small set of patients whose immune systems were able to generate rare antibodies able to vanquish most strains of the lethal virus. And over the weekend a team of scientists from South Africa and the U.S. say that one woman--dubbed CAP256-VRC26--may have offered a key to do just that.
The information comes from Genetic Epidemiology Research on Aging (GERA), a cohort of more than 100,000 adults with an average age of 63 years old.
George Washington University and the National Institutes of Health this week took high-speed Internet connections to the next level. The organizations are using their new 100-Gbps links to the Internet2 Network to trial 40-Gbps transfers of genomics data.
The NIH has added a huge amount of medical data--from a diverse group of more than 78,000 people with an average age of 63--to Genetic Epidemiology Research on Aging, one of the nation's largest and most diverse genomics projects.
Sedia Biosciences will use a new $1 million NIH grant to bring forward an HIV diagnostic test it hopes will better assess recently infected individuals and how advanced the virus has become inside the body.
While antiretroviral therapies and preventive measures have helped lessen the impact of HIV, leaders at the National Institutes of Health think a safe, moderately effective vaccine is still needed.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Thanks to some high-profile failures to replicate preclinical findings in some of the world's leading journals, the call for reform has reached a fever pitch, and National Institutes of Health Director Francis Collins has taken up the baton.
Infecting healthy volunteers with influenza in a controlled environment will allow researchers to track each step of the immune response, potentially revealing answers to some fundamental questions limiting the effectiveness of vaccines.